Extractables and Leachables: An Overview of Emerging Challenges - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Extractables and Leachables: An Overview of Emerging Challenges
Extractables and leachables are a growing concern for pharmaceutical manufacturers and regulatory bodies.

Pharmaceutical Technology
Volume 32, Issue 8

FDA's requirements, as spelled out in the guidance for industry Container Closure Systems for Packaging Human Drugs and Biologics, describe understanding the levels of extractables and leachables, the test methods related to these contaminants, and other considerations relating to packaging components (8). This guidance also addresses the review and evaluation of packaging requirements. According to this document,
"each new drug application (NDA) or abbreviated new drug application (ANDA) should contain enough information to demonstrate that a proposed container-closure system and its components are suitable for its intended use. The type and extent of information required will depend on the dosage form and route of administration. Qualification and quality review is applied to packaging materials and to the actual dosage form. Packaging suitability is based on four attributes: protection, safety, compatibility and performance (function and/or drug delivery). For injectable dosage forms, the document outlines the tests required to show that interaction is not a problem. Associated components, such as those used only at the time a dosage is administered, self-adhesive labels and secondary packaging materials are also included in the review process" (5, 9).

The guidance also specifies that:
"... packaging components should be constructed of materials that will not leach harmful or undesirable amounts of substances to which a patient will be exposed when being treated with a drug product. These applications should contain an extraction study on the packaging component to determine which chemicals and/or residues may migrate into the dosage form, and second a toxicological evaluation of the substances..." (9, 14).

Drug manufacturers invest a tremendous amount of time and money to identify, quantify, and minimize impurities related to their drug products so that FDA can make appropriate decisions regarding drug product purity and safety. An area of increasing concern and scrutiny for FDA's Center for Drug Evaluation and Research (CDER) is the potential adulteration of drug products by extractable and leachable compounds that enter a drug product from a container, closure system, disposable, or device (10, 11).

Addressing this concern, 21 CFR 211.94(a) states: "Drug product containers and closures shall not be reactive, additive, or absorptive so as to alter the safety, identity, strength, quality, or purity of the drug beyond the official or established requirement" (11, 12). In addition to FDA's 21 CFR 211, regulations governing primary packaging are contained in the FDA guidance, Container Closure Systems for Packaging Human Drugs and BiologicsChemistry, Manufacturing and Controls Documentations, and the United States Pharmacopoeia's General Chapter 25 (9, 12, 13).

In May of 2005, the European Agency for the Evaluation of Medical Products (EMEA) issued the Guideline on Plastic Immediate Packaging Materials, which indicates that
"the aim of extraction studies is to determine those additives (such as antioxidants, plasticizers, catalysts, initiators, etc.) that might be extracted by the active substance in contact with the plastic material. Extraction studies are considered necessary for plastic materials used for container systems of nonsolid active substances and nonsolid dosage forms."

EMEA specifies that interaction studies between the plastic packaging material and the active substance should be evaluated. In addition, migration studies are deemed "necessary when extraction studies have resulted in one or several extractables" (14).

The qualification and quality control of all components coming into contact with the drug formulation has become an integral part of any FDA application process. Investigation of potential extractables and leachables must be carried out under International Conference on Harmonization (ICH) and USP guidelines in a current Good Manufacturing Practices (CGMP)-compliant laboratory. These activities may be very time consuming and require a wide array of analytical techniques and expertise (6, 10, 11, 14).

By using clean raw materials with minimal processing additives, extractables and leachables are minimized. FDA levels of concern for extractables and leachables vary for different pharmaceutical products, depending on the route of administration and the dosage form. As the level of concern increases, so do the requirements for characterizing extractables and leachables (10).

Inhalation and injectable drug products have stringent requirements. There are product-specific draft guidelines for metered dose inhalers (MDIs), dry powder inhalers (DPIs), nasal sprays, inhalation solutions, suspensions, and sprays. The identity and concentration of leachables in inhalation and nasal drug products must be monitored throughout the products' shelf life since the product consists of the dosage form and the container/closure system (6).

FDA's interest in this area is believed to be in response to a particular incident in the late-1990s in which an MDI was found to contain harmful leachables (15). Leachables in inhaled drug products tend to arise from polymers, elastomers, adhesives and curing agents, metal components, dyes and pigments, and mold release agents (17, 20). In another case, the supplier of the rubber O-ring in a device wasn't accustomed to the standards of the pharmaceutical industry and formulated the rubber using some polynuclear aromatics (PNAs), creating a health risk. Since then, the agency has asked for more analysis with submissions (15). Some other cases are reports of PNAs in elastomers, PNAs in MDIs, volatile N-nitrosamines were reported to be present in baby bottle rubber nipples, and mercaptobenzothiazole (2 MBT) in elastomers (20, 33).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here